Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of AZD9550 and AZD6234 in Hepatic Impairment
NCT07546760Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of AZD9550 and lenbelintide in obesity (3 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Curve from zero to infinity, Area Under the Curve from zero to the last quantifiable concentration and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
AZD9550lenbelintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07546760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07546760.